ANAB
AnaptysBio, Inc. Common Stock
stock NASDAQ

AnaptysBio, Inc. (Nasdaq: ANAB) announced that its Board of Directors has authorized a Stock Repurchase Plan under which the Company may repurchase up to $75,000,000 of the Company’s outstanding common stock, par value $0.001 per share.
Anaptys has cash, cash equivalents and investments greater than $420 million as of December 31, 2024, and anticipates receipt of a $75 million commercial sales milestone payment from GSK in 2025 or 2026. Notwithstanding the potential full execution of the Stock Repurchase Plan, the Company reiterates its previous cash runway guidance through year-end 2027 to execute its research and development plan, excluding potential future royalties from its GSK immuno-oncology financial collaboration.
The shares may be repurchased from time to time in open market transactions, or other means in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and Rule 10b-18 of the Exchange Act. The timing, number of shares repurchased, and prices paid for the stock under this program will depend on general business and market conditions as well as corporate and regulatory limitations, prevailing stock prices, and other considerations. The Stock Repurchase Plan will expire on December 31, 2025, may be suspended or discontinued at any time, and does not obligate the company to acquire any amount of common stock.
[https://www.globenewswire.com/news-release/2025/03/24/3047939/0/en/Anaptys-Announces-Stock-Repurchase-Plan.html](https://www.globenewswire.com/news-release/2025/03/24/3047939/0/en/Anaptys-Announces-Stock-Repurchase-Plan.html)
https://preview.redd.it/xxd1c79jdnqe1.jpg?width=1222&format=pjpg&auto=webp&s=30ec403eec745d6194aabfc01d8526b753608d4c

AnaptysBio, Inc. (Nasdaq: ANAB) announced that its Board of Directors has authorized a Stock Repurchase Plan under which the Company may repurchase up to $75,000,000 of the Company’s outstanding common stock, par value $0.001 per share.
Anaptys has cash, cash equivalents and investments greater than $420 million as of December 31, 2024, and anticipates receipt of a $75 million commercial sales milestone payment from GSK in 2025 or 2026. Notwithstanding the potential full execution of the Stock Repurchase Plan, the Company reiterates its previous cash runway guidance through year-end 2027 to execute its research and development plan, excluding potential future royalties from its GSK immuno-oncology financial collaboration.
The shares may be repurchased from time to time in open market transactions, or other means in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and Rule 10b-18 of the Exchange Act. The timing, number of shares repurchased, and prices paid for the stock under this program will depend on general business and market conditions as well as corporate and regulatory limitations, prevailing stock prices, and other considerations. The Stock Repurchase Plan will expire on December 31, 2025, may be suspended or discontinued at any time, and does not obligate the company to acquire any amount of common stock.
[https://www.globenewswire.com/news-release/2025/03/24/3047939/0/en/Anaptys-Announces-Stock-Repurchase-Plan.html](https://www.globenewswire.com/news-release/2025/03/24/3047939/0/en/Anaptys-Announces-Stock-Repurchase-Plan.html)
https://preview.redd.it/xxd1c79jdnqe1.jpg?width=1222&format=pjpg&auto=webp&s=30ec403eec745d6194aabfc01d8526b753608d4c